Study #2019-0335
A Phase 1 Dose Escalation Study To Assess Safety and Efficacy Of ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 positive tumors (SURPASS STUDY)
MD Anderson Study Status
Not Accepting
Treatment Agent
Description
This study will investigate the safety and tolerability of ADP-A2M4CD8 T-cell therapy in subjects who have the appropriate human leukocyte antigen (HLA) and MAGE-A4 tumor antigen. Tumor indications include endometrial, esophageal, esophagogastric junction (EGJ), gastric, head and neck, melanoma, non-small cell lung (NSCLC), ovarian or urothelial cancer.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Endometrial Cancer;Esophageal Cancer;Esophagogastric Junction (EGJ);Gastric (Stomach) Cancer;Head and Neck Cancer;Melanoma;Ovarian Cancer;Non-small Cell Lung (NSCLC);Urothelial Cancer
Study phase:
Phase I
Physician name:
David Sanghyun Hong
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-844-252-9709
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.